Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | MLNR | O43193 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 2/20 | 0.38 |
| ▸ | SCD | O00767 | 2/20 | 0.38 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4838582 | 0.80 | SIGMAR1 (0.40) | — | |
| SCHEMBL1698586 | 0.80 | GPR119 (0.64) | GPR119ALK | |
| Hydrochloric Acid SCHEMBL6343764 | 0.79 | MLNR (0.38) | MLNRSCDCYP3A4TTK | |
| SCHEMBL6345619 | 0.77 | SCD (0.52) | SCD | |
| SCHEMBL6215082 | 0.76 | PTPRB (0.43) | GPR119USP30 | |
| SCHEMBL6354873 | 0.76 | EPHX2 (0.44) | GPR119LIPESCDEPHX2USP30 | |
| SCHEMBL6353247 | 0.76 | GPR119 (0.42) | GPR119LIPEPIK3CD | |
| SCHEMBL1698819 | 0.76 | GPR119 (0.42) | GPR119MLNRLNPEPEPHX2 | |
| SCHEMBL5393341 | 0.74 | GPR119 (0.34) | GPR119SCDUSP30 | |
| SCHEMBL6346955 | 0.73 | NOS2 (0.54) | GPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878725-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040242656-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1289950-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030078438-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2003-04-24 | — | — | US | disclosed |
| EP-1289950-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096296-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078438-A1 | Serine protease inhibitors | HPN, LPXN, PRSS1 | GPR119 2924/4885MLNR 1670/4885LIPE 82/4885 |
| US-20040242656-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | GPR119 2989/4885MLNR 2109/4885LIPE 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.